Pulmonary drug delivery systems are used to the treatment of various respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD), delivering locally acting drugs directly to their site of action. Advantages of pulmonary drug delivery systems over oral drugs is the excellent capability of absorbing pharmaceuticals, due to the large absorptive surface area of lungs (approximately 70-140 m2 in adult humans having extremely thin absorptive mucosal membrane) and good blood supply.
This report aims to provide a comprehensive presentation of the global market for Pulmonary Drug Delivery Systems, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pulmonary Drug Delivery Systems. This report contains market size and forecasts of Pulmonary Drug Delivery Systems in global, including the following market information:
- Global Pulmonary Drug Delivery Systems Market Revenue, 2018-2023, 2024-2029, ($ millions)
- Global Pulmonary Drug Delivery Systems Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Pulmonary Drug Delivery Systems companies in 2022 (%)
The global Pulmonary Drug Delivery Systems market was valued at US$ 3134.3 million in 2022 and is projected to reach US$ 4129.9 million by 2029, at a CAGR of 4.0% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The major players in global Pulmonary Drug Delivery Systems market include 3M, GSK, AstraZeneca, etc. The top 3 players occupy about 60% shares of the global market. Europe and North America are main markets, they occupy over 75% of the global market. Metered Dose Inhaler (MDI) is the main type, with a share over 60%. COPD is the main application, which holds a share over 50%.
We surveyed the Pulmonary Drug Delivery Systems manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Pulmonary Drug Delivery Systems Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Pulmonary Drug Delivery Systems Market Segment Percentages, by Type, 2022 (%)
- Nebulizers
- Dry Powder Inhaler (DPI)
- Metered Dose Inhaler (MDI)
Global Pulmonary Drug Delivery Systems Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Pulmonary Drug Delivery Systems Market Segment Percentages, by Application, 2022 (%)
Global Pulmonary Drug Delivery Systems Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Pulmonary Drug Delivery Systems Market Segment Percentages, By Region and Country, 2022 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Pulmonary Drug Delivery Systems revenues in global market, 2018-2023 (Estimated), ($ millions)
- Key companies Pulmonary Drug Delivery Systems revenues share in global market, 2022 (%)
- Key companies Pulmonary Drug Delivery Systems sales in global market, 2018-2023 (Estimated), (K Units)
- Key companies Pulmonary Drug Delivery Systems sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
- 3M
- GSK
- AstraZeneca
- Cipla
- Chiesi
- Boehringer Ingelheim
- Aptar
- Novartis
- Philips Respironics
- Omron Healthcare
- PARI
- Skyepharma
- CareFusion
- Shanghai Huarui
- Taian Character
- Chia Tai Tianqing
- Outline of Major Chapters:
- Chapter 1: Introduces the definition of Pulmonary Drug Delivery Systems, market overview.
- Chapter 2: Global Pulmonary Drug Delivery Systems market size in revenue and volume.
- Chapter 3: Detailed analysis of Pulmonary Drug Delivery Systems manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
- Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
- Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
- Chapter 6: Sales of Pulmonary Drug Delivery Systems in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
- Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
- Chapter 8: Global Pulmonary Drug Delivery Systems capacity by region & country.
- Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
- Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
- Chapter 11: The main points and conclusions of the report.
